iBio Inc. Sells Preclinical PD-1 Agonist Antibody Program to Otsuka Pharmaceutical: A Strategic Move for Both Companies.
Share this post
Biotechnology Company Announces Sale of…
Share this post
iBio Inc. Sells Preclinical PD-1 Agonist Antibody Program to Otsuka Pharmaceutical: A Strategic Move for Both Companies.